|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang T, Nelson RA, Bogardus A and Grannis
FW Jr: Five-year lung cancer survival: Which advanced stage
nonsmall cell lung cancer patients attain long-term survival?
Cancer. 116:1518–1525. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pao W and Girard N: New driver mutations
in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Couraud S, Zalcman G, Milleron B, Morin F
and Souquet PJ: Lung cancer in never smokers - a review. Eur J
Cancer. 48:1299–1311. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cornfield J, Haenszel W, Hammond EC,
Lilienfeld AM, Shimkin MB and Wynder EL: Smoking and lung cancer:
Recent evidence and a discussion of some questions. 1959. Int J
Epidemiol. 38:1175–1191. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ding L, Getz G, Wheeler DA, Mardis ER,
McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan
MB, et al: Somatic mutations affect key pathways in lung
adenocarcinoma. Nature. 455:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shtivelman E, Hensing T, Simon GR, Dennis
PA, Otterson GA, Bueno R and Salgia R: Molecular pathways and
therapeutic targets in lung cancer. Oncotarget. 5:1392–1433. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bassères DS, Tizzei EV, Duarte AA, Costa
FF and Saad ST: ARHGAP10, a novel human gene coding for a
potentially cytoskeletal Rho-GTPase activating protein. Biochem
Biophys Res Commun. 294:579–585. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dubois T, Paléotti O, Mironov AA, Fraisier
V, Stradal TE, De Matteis MA, Franco M and Chavrier P:
Golgi-localized GAP for Cdc42 functions downstream of ARF1 to
control Arp2/3 complex and F-actin dynamics. Nat Cell Biol.
7:353–364. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lazarini M, Traina F, Machado-Neto JA,
Barcellos KS, Moreira YB, Brandão MM, Verjovski-Almeida S, Ridley
AJ and Saad ST: ARHGAP21 is a RhoGAP for RhoA and RhoC with a role
in proliferation and migration of prostate adenocarcinoma cells.
Biochim Biophys Acta. 1832:365–374. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sousa S, Cabanes D, Archambaud C, Colland
F, Lemichez E, Popoff M, Boisson-Dupuis S, Gouin E, Lecuit M,
Legrain P, et al: ARHGAP10 is necessary for alpha-catenin
recruitment at adherens junctions and for Listeria invasion. Nat
Cell Biol. 7:954–960. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Borges L, Bigarella CL, Baratti MO,
Crosara-Alberto DP, Joazeiro PP, Franchini KG, Costa FF and Saad
ST: ARHGAP21 associates with FAK and PKCzeta and is redistributed
after cardiac pressure overload. Biochem Biophys Res Commun.
374:641–646. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Anthony DF, Sin YY, Vadrevu S, Advant N,
Day JP, Byrne AM, Lynch MJ, Milligan G, Houslay MD and Baillie GS:
β-Arrestin 1 inhibits the GTPase-activating protein function of
ARHGAP21, promoting activation of RhoA following angiotensin II
type 1A receptor stimulation. Mol Cell Biol. 31:1066–1075. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wong NC, Bhadri VA, Maksimovic J,
Parkinson-Bates M, Ng J, Craig JM, Saffery R and Lock RB: Stability
of gene expression and epigenetic profiles highlights the utility
of patient-derived paediatric acute lymphoblastic leukaemia
xenografts for investigating molecular mechanisms of drug
resistance. BMC Genomics. 15:4162014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Azzato EM, Pharoah PD, Harrington P,
Easton DF, Greenberg D, Caporaso NE, Chanock SJ, Hoover RN, Thomas
G, Hunter DJ, et al: A genome-wide association study of prognosis
in breast cancer. Cancer Epidemiol Biomarkers Prev. 19:1140–1143.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Luo N, Guo J, Chen L, Yang W, Qu X and
Cheng Z: ARHGAP10, downregulated in ovarian cancer, suppresses
tumorigenicity of ovarian cancer cells. Cell Death Dis.
7:e21572016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES, et al: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Teng Y, Wang X, Wang Y and Ma D:
Wnt/β-catenin signaling regulates cancer stem cells in lung cancer
A549 cells. Biochem Biophys Res Commun. 392:373–379. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bigarella CL, Borges L, Costa FF and Saad
ST: ARHGAP21 modulates FAK activity and impairs glioblastoma cell
migration. Biochim Biophys Acta. 1793:806–816. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Carles A, Millon R, Cromer A, Ganguli G,
Lemaire F, Young J, Wasylyk C, Muller D, Schultz I, Rabouel Y, et
al: Head and neck squamous cell carcinoma transcriptome analysis by
comprehensive validated differential display. Oncogene.
25:1821–1831. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bogenrieder T and Herlyn M: Axis of evil:
Molecular mechanisms of cancer metastasis. Oncogene. 22:6524–6536.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Su JL, Yang PC, Shih JY, Yang CY, Wei LH,
Hsieh CY, Chou CH, Jeng YM, Wang MY, Chang KJ, et al: The
VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells.
Cancer Cell. 9:209–223. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cockett MI, Murphy G, Birch ML, O'Connell
JP, Crabbe T, Millican AT, Hart IR and Docherty AJ: Matrix
metalloproteinases and metastatic cancer. Biochem Soc Symp.
63:295–313. 1998.PubMed/NCBI
|
|
24
|
Kerbel RS and Kamen BA: The
anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer.
4:423–436. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Polakis P: Wnt signaling in cancer. Cold
Spring Harb Perspect Biol.
4:a0080522012.doi:10.1101/cshperspect.a008052. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tang Y, Simoneau AR, Liao WX, Yi G, Hope
C, Liu F, Li S, Xie J, Holcombe RF, Jurnak FA, et al: WIF1, a Wnt
pathway inhibitor, regulates SKP2 and c-myc expression leading to
G1 arrest and growth inhibition of human invasive urinary bladder
cancer cells. Mol Cancer Ther. 8:458–468. 2009. View Article : Google Scholar : PubMed/NCBI
|
